Transdermal delivery of antiparkinsonian agent, benztropine. I. Effect of vehicles on skin permeation

International Journal of Pharmaceutics

Volumn 192, Issue 2, 1999, Pages 159-172

  Gorukanti, Sudhir R ^a   Li, Lianli ^a   Kim, Kwon H ^a  

^a St Albert's Hall   (United States)

Author keywords

Benztropine free base and mesylate salt; Enhanced skin permeability; Isopropyl myristate; Short chain alkanols; Single and binary enhancers; Transdermal delivery

Indexed keywords

2 PROPANOL; ALCOHOL; ALKANOL; ANTIPARKINSON AGENT; BENZATROPINE; BENZATROPINE MESILATE; BUFFER; DRUG VEHICLE; MACROGOL 400; MINERAL OIL; MYRISTIC ACID ISOPROPYL ESTER; PENETRATION ENHANCING AGENT; PROPYLENE GLYCOL; SILICONE; SOLVENT; TERT BUTYL ALCOHOL; WATER;

ANIMAL TISSUE; ARTICLE; CADAVER; CONTROLLED STUDY; DERMIS; DRUG POTENTIATION; DRUG SOLUBILITY; EPIDERMIS; FEMALE; HUMAN; HUMAN TISSUE; HYDROPHILICITY; LIPOPHILICITY; MOUSE; NONHUMAN; NUDE MOUSE; PARTITION COEFFICIENT; PH; PRIORITY JOURNAL; SKIN PENETRATION; SKIN PERMEABILITY; STRATUM CORNEUM; STRUCTURE ACTIVITY RELATION; TRANSDERMAL DRUG ADMINISTRATION;

EID: 0032732922     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(99)00305-1     Document Type: Article

References (27)

1. Albert A., Sergeant E.P. The Determination of Ionization Constants. third ed:1984;166-167 Chapman and Hill, New York.
2. Catz P., Friend D.R. Effect of cosolvents on ethyl acetate enhanced percutaneous absorption of levonorgestrel. J. Controlled Release. 12:1990;171-180.
3. Chien Y.W. Development of transdermal drug delivery systems. Drug Dev. Ind. Pharm. 13:1987;589-651.
4. Chien Y.W., Xu H., Chiang C.C., Huang Y.C. Transdermal controlled administration of indomethacin. Pharm. Res. 5:1988;103-106.
5. Cooper E.R., Merritt E.W., Smith R.L. Effect of fatty acids and alcohols on the penetration of acyclovir across human skin in vitro. J. Pharm. Sci. 74:1985;688-690.
6. Flaherty J.F., Gidal B.E. Parkinson's disease. Young L.Y., Koda-Kimnle M.A. Applied Therapeutics: The Clinical Use of Drugs. sixth ed:1995;51 Applied Therapeutics, Vancouver, WA.
7. Flynn G.L. Mechanism of percutaneous absorption from physicochemical evidence. Bronaugh R.L., Maibach H.I. Percutaneous Absorption. 1983;17-42 Marcel Dekker, New York.
8. Flynn G.L., Stewart B. Percutaneous drug penetration: choosing candidates for transdermal development. Drug Dev. Res. 13:1988;169-185.
9. Ghosh T.K., Banga A.K. Methods of enhancement of transdermal drug delivery: chemical permeation enhancers. Pharm. Technol. 17:1993;68-76.
10. Goldberg-Cettina M., Lie P., Nightingale J., Kurihara-Bergstrom T. Enhanced transdermal delivery of estradiol in vitro using binary vehicles of isopropyl myristate and short-chain alcohols. Int. J. Pharm. 114:1995;237-245.
11. Golden G.M., McKie J.E., Potts R.O. Role of stratum corneum lipid fluidity in transdermal drug flux. J. Pharm. Sci. 76:1987;25-28.
12. Goto S., Uchida T., Lee C.K., Yasutake T., Zhang J. Effect of various vehicles on ketoprofen permeation across excised hairless mouse skin. J. Pharm. Sci. 82:1993;959-983.
13. He, H., 1995. Metabolic and pharmacokinetic studies of benztropine and trihexyphenidyl. Ph.D. Thesis, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
14. Malkinson F.D., Rothman S. Percutaneous absorption. Marchionini A., Spier H.W. Handbuch der Haut-und Geschlecht-krankheiten. 1963;90-156 Erganzungswerk Bd, Berlin.
15. Moriyama S. Studies on percutaneous penetration. Jpn. J. Dermatol. 70:1960;919.
16. Nelson M.V., Berchou R.C., LeWitt P.A. Parkinson's disease. DiPiro J.T., Talbert R.A. Pharmacotherapy: A Pathologic Approach. third ed:1997;1243-1257 Appleton and Lange, Stamford, CT.
17. Obata Y., Takayama K., Maitani Y., Machita Y., Nagai T. Effect of ethanol on skin permeation of nonionized and ionized diclofenac. Int. J. Pharm. 89:1993;191-198.
18. Pardo A., Shiri Y., Cohen S. Percutaneous absorption of physostigmine: optimization of delivery from a binary solvent by thermodynamic control. J. Pharm. Sci. 79:1990;573-578.
19. Rolf D. Chemical and physical methods of enhancing transdermal drug delivery. Pharm. Technol. 12:1988;130-140.
20. Scheuplein R.J., Blank I.H. Permeability of the skin. Physiol. Rev. 51:1971;702-747.
21. Sloan K.B., Koch S.A., Siver K.G., Flowers F.P. Use of solubility parameters of drug and vehicle to predict flux through skin. J. Invest. Dermatol. 87:1986;244-252.
22. Standaert D.G., Young A.B. Treatment of central nervous system degenerative disorders. Hardman J.G, Limbird L.E. Goodman and Gilman's The Pharmacological Basis of Therapeutics. ninth ed:1996;503-513 McGraw-Hill, New York.
23. Stoughton R.B. Animal models for in vitro percutaneous absorption. Maibach H. Animal Models in Dermatology: Relevance to Human Dermatopharmacology and Dermatotoxicology. 1975;121 Churchill Livingstone, London.
24. Vaughan C.D. Using solubility parameters in cosmetic formulation. J. Soc. Cosmet. Chem. 36:1985;319-333.
25. Walters K.A. Penetration enhancers and their use in transdermal therapeutic systems. Jadgraft J., Guy R.H. Transdermal Drug Delivery: Developmental Issues and Research Initiatives. 1989;197-246 Marcel Dekker, New York
26. Yamashita F., Yoshioka T., Koyama Y., Okamoto H., Sezaki H., Hashida M. Analysis of skin penetration enhancement based on a two-layer skin diffusion model with polar and nonpolar routes in the stratum corneum: dose-dependent effect of 1-geranylazacycloheptane-2-one on drugs with different lipophilicities. Biol. Pharm. Bull. 16(7):1993;690-697.
27. Zatz J.L., Sarpotdar P.P. Influence of vehicles on skin penetration. Kydonieus A.F., Berner B. Transdermal Delivery of Drugs. 2:1987;85-98 CRC Press, Boca Raton, FL.